We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more
Kushwah S et al. · Current neuropharmacology (2023)
A rich knowledge base of traditional herbal plants (Turmeric, Gingko, Ashwagandha, Shankhpushpi, Giloy, Gotu kola, Garlic, Tulsi, Ginger, and Cinnamon) combined with modern science could suggest new functional leads for Alzheimer's drug discovery.
In this article Ayurveda, the ancient Indian herbal medicine system based on multiple clinical and experimental, evidence have been reviewed for treating AD and improving brain functioning.
This article presents a modern perspective on the herbs available in the ancient Indian medicine system as well as their possible mechanisms of action for AD treatment.
Overall, nearly one-quarter (23%) of adults currently take a supplement to maintain or improve brain health or delay and reverse dementia.
However, other botanicals that affect stress, focus, attention, and sleep have also been procured by dietary supplement companies developing products for improving both, short and long-term brain health.
Botanicals are discussed in terms of available clinical efficacy data and current safety profiles.
3Neuroprotective effects in Alzheimer's diseaseSystematic ReviewCited 115×2021
It is hoped that these medicinal plants can be used in drug discovery programs for identifying safe and efficacious small molecules for AD.
Gregory J et al. · Biomolecules (2021)
Methods-This article systematically reviews recent studies that have investigated the role of neuroprotective herbs and their bioactive compounds for dementia associated with Alzheimer's disease and pre-Alzheimer's disease.
PubMed Central, Scopus, and Google Scholar databases of articles were collected, and abstracts were reviewed for relevance to the subject matter.
Conclusions-Medicinal plants have great potential as part of an overall program in the prevention and treatment of cognitive decline associated with AD.
However, detailed scientific approaches on clinical trials regarding health benefits and nutritional values of C. asiatica are limited, hindering the perception of its benefits, mechanisms, and tox...
Chandrika UG et al. · Advances in food and nutrition research (2015)
However, detailed scientific approaches on clinical trials regarding health benefits and nutritional values of C. asiatica are limited, hindering the perception of its benefits, mechanisms, and toxicity in order to develop new drug prototypes.
In vitro studies have shown that the method of processing C. asiatica has an impact on its nutritional values and health-related beneficial compounds.
The composition of its compounds is influenced by different biotic and abiotic factors which need to be studied in detail to provide information to the public in order to maximize the usage of this valuable plant.
6Clinical signs improvement in hepatic encephalopathyRCTCited 2×n=66 · small study2006
In group combined treatment was significant improvement of clinical signs, psychometric tests, electroencephalography and serum biochemistry than in group with standard therapy, on term of 2 to 5 weeks.
Kaziulin AN et al. · Voprosy pitaniia (2006)
In group combined treatment was significant improvement of clinical signs, psychometric tests, electroencephalography and serum biochemistry than in group with standard therapy, on term of 2 to 5 weeks.
Formula includes extracts of plants: Bacopa monneria, Gingko biloba, Cat's Claw, Gotu Kola, Rosemary.
Further research warranted to confirm findings
7RCTCited 26×n=36 · small study2007
These finding do not support the use of a ginkgo biloba-containing supplement for improving cognitive function or quality of life in cognitively intact, older, healthy adults.
Carlson JJ et al. · Journal of the American Dietetic Association (2007)
Seventy-eight subjects (87%) completed both baseline and 4-month testing (n=36 in placebo group, n=42 in ginkgo biloba group).
One of six cognitive tests indicated significant protocol differences at 4 months (P=0.03), favoring the placebo.
These finding do not support the use of a ginkgo biloba-containing supplement for improving cognitive function or quality of life in cognitively intact, older, healthy adults.